OncLive SOSS
  • MJHLS Brand Logo

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2021 MJH Life Sciences™ and OncLive. All rights reserved.

New Fixed-Dose Subcutaneous Option for HER2+ Breast Cancer

September 24, 2020
Mark Pegram, MD, Stanford Women's Cancer Center

,
Chau Dang, MD, Memorial Sloan Kettering Westchester

,
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

Dr. Dumbrava on the Mechanism of Action of BDC-1001 in Advanced HER2-Expressing Breast Cancer
Dr. Harismendy on the Challenges Faced With Molecular Testing in DCIS
Big Data Tool Finds Variations in Treatment and Costs Across 3 Cancer Types
x